Stock AnalizAlphatec Holdings, Inc. ATEC
Medical/Dental Instruments · IPO 2006 · data as of November 13, 2026
Alphatec Holdings, Inc. (ATEC) is a healthcare company listed in the US with a market value of about $1.1B. In the twelve months to September 30, 2026 it had revenue of $840M and net income of -$87M, a net margin of -10.3%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 357.7, 5-year revenue growth of 39% a year, a 5-year average ROIC of -26%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 84% below the current price.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $840M | $764M | $612M | $482M | $351M | $243M | $145M | $113M | $92M | $102M | $120M |
| Net income | -$87M | -$143M | -$162M | -$187M | -$151M | -$143M | -$79M | -$57M | -$29M | -$2M | -$30M |
| Free cash flow | $3M | $3M | -$128M | -$159M | -$125M | -$142M | -$70M | -$46M | -$32M | -$16M | -$19M |
| EPS (diluted) | $-0.56 | $-0.96 | $-1.13 | $-1.54 | $-1.46 | $-1.49 | $-1.18 | $-1.09 | $-1.20 | $-1.08 | $-3.49 |
| Net margin | -10.3% | -18.8% | -26.5% | -38.7% | -43.1% | -58.8% | -54.5% | -50.2% | -31.6% | -2.2% | -24.9% |
| ROIC | — | -13.5% | -18.1% | -27.9% | -40.5% | -29.1% | -26.9% | -44.0% | -32.0% | -55.1% | -168.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $12.93, 83% above the current price; targets range from $8.00 to $24.00; the consensus rating is “Strong buy”; expected EPS is $0.29 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Alphatec stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 84% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Alphatec pay a dividend?
Not currently.
Is Alphatec a good stock to buy?
We do not give buy or sell advice. Alphatec scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.